Catalyst Watch: Intel's AI event, Oracle earnings and CAVA IPO lockup expiration

Stock Information for Arlington Asset Investment Corp Class A (new)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arlington Asset Investment Corp Class A (new)

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune Announces First Quarter 2025 Financial Results and Business Update
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress(TM)
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Altimmune to Present at Upcoming EASL International Liver Congress(TM) 2025
Altimmune to Participate in the Citizens Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.